Venus Medtech (Hangzhou), Inc. Class H (HK:2500) has released an update.
Venus Medtech (Hangzhou), Inc. is actively addressing queries from the Stock Exchange regarding its Forensic Investigation, Internal Control Review, and management integrity, following key findings and a trading halt. The company has not yet met the conditions for resuming trading as per the Resumption Guidance but continues to keep shareholders informed on progress. The recent announcement supplements previous updates, maintaining that all other information remains consistent with the Second Quarterly Update.
For further insights into HK:2500 stock, check out TipRanks’ Stock Analysis page.
